These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19410324)

  • 1. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis.
    Rudolph G; Gotthardt D; Klöters-Plachky P; Kulaksiz H; Rost D; Stiehl A
    J Hepatol; 2009 Jul; 51(1):149-55. PubMed ID: 19410324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival.
    Rudolph G; Gotthardt D; Kloeters-Plachky P; Rost D; Kulaksiz H; Stiehl A
    J Hepatol; 2010 Aug; 53(2):313-7. PubMed ID: 20472317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biliary candida infections in primary sclerosing cholangitis.
    Kulaksiz H; Rudolph G; Kloeters-Plachky P; Sauer P; Geiss H; Stiehl A
    J Hepatol; 2006 Nov; 45(5):711-6. PubMed ID: 16979779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment.
    Gotthardt DN; Rudolph G; Klöters-Plachky P; Kulaksiz H; Stiehl A
    Gastrointest Endosc; 2010 Mar; 71(3):527-34. PubMed ID: 20189511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.
    Stiehl A; Rudolph G; Klöters-Plachky P; Sauer P; Walker S
    J Hepatol; 2002 Feb; 36(2):151-6. PubMed ID: 11830325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis.
    Tischendorf JJ; Krüger M; Trautwein C; Duckstein N; Schneider A; Manns MP; Meier PN
    Endoscopy; 2006 Jul; 38(7):665-9. PubMed ID: 16673310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study.
    Stiehl A; Rudolph G; Sauer P; Benz C; Stremmel W; Walker S; Theilmann L
    J Hepatol; 1997 Mar; 26(3):560-6. PubMed ID: 9075663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dominant stenoses on the serum level of the tumor marker CA19-9 in patients with primary sclerosing cholangitis.
    Petersen-Benz C; Stiehl A
    Z Gastroenterol; 2005 Jun; 43(6):587-90. PubMed ID: 15986288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
    Garioud A; Seksik P; Chrétien Y; Corphechot C; Poupon R; Poupon RE; Chazouillères O
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor outcome in progressive sclerosing cholangitis after septic shock.
    Kulaksiz H; Heuberger D; Engler S; Stiehl A
    Endoscopy; 2008 Mar; 40(3):214-8. PubMed ID: 18264887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary sclerosing cholangitis: the role of endoscopic therapy.
    Stiehl A
    Semin Liver Dis; 2006 Feb; 26(1):62-8. PubMed ID: 16496234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of primary sclerosing cholangitis].
    Stiehl A; Benz C; Sauer P
    Praxis (Bern 1994); 2000 May; 89(22):975-7. PubMed ID: 10893998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
    Rudolph G; Kloeters-Plachky P; Rost D; Stiehl A
    Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):487-91. PubMed ID: 17489059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture.
    Fracchia M; Soubrane O; Houssin D; Galatola G
    Ital J Gastroenterol; 1995; 27(8):430-5. PubMed ID: 8775469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis.
    Pohl J; Ring A; Stremmel W; Stiehl A
    Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):69-74. PubMed ID: 16357622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
    Hay JE
    Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer.
    Linder S; Söderlund C
    Hepatogastroenterology; 2001; 48(38):387-92. PubMed ID: 11379315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile duct bacterial isolates in primary sclerosing cholangitis and certain other forms of cholestasis--a study of bile cultures from ERCP.
    Björnsson ES; Kilander AF; Olsson RG
    Hepatogastroenterology; 2000; 47(36):1504-8. PubMed ID: 11148988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current diagnosis and management of primary sclerosing cholangitis.
    Tischendorf JJ; Geier A; Trautwein C
    Liver Transpl; 2008 Jun; 14(6):735-46. PubMed ID: 18508363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.